Novo Nordisk A/S

NYSE:NVO

Drug Manufacturers - General

Healthcare
$39.43 -1.09%

-$0.48 today

Market cap
$173.82B
Beta
0.35
P/E (TTM)
10.2
EPS (TTM)
$27.45
Dividend yield
4.18%
52W Low $35.12High $74.38

Volume 16.12M

Average 16.05M

NVO Deferred Tax Liabilities

Taxes owed in future periods because of timing differences between accounting and tax rules.

Novo Nordisk A/SNYSE: NVO

Deferred Tax Liabilities · Q2 FY2026 · quarter ended Jun 2026

Deferred tax liabilities falls 56.4% from a year ago

Deferred tax liabilities stood at DKK 4.27B at the end of Q2 FY2026, down 56.4% from a year earlier and down 14.7% from the prior quarter. Over 3 fiscal years it compounded at -2.2% a year.

Context

  • Deferred tax liabilities amounted to 0.7% of total assets at the end of Q2 FY2026, down 1.3 pp from a year earlier.
  • Deferred tax liabilities increased in 2 of the last 3 fiscal years.

What to watch

Whether deferred tax liabilities keeps falling in the next quarterly balance sheet after a -56.4% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
DKK 4.27B-14.7% QoQ
Last fiscal yearDec 2025
DKK 6.61B+21.8% YoY
Year agoJun 2025
DKK 9.8B-56.4% since
Deferred Tax Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-56.4%——
1 year+21.8%——
3-year CAGR-2.2%——
5-year CAGR——
10-year CAGR——

Deferred Tax Liabilities history

DKK · from the balance sheet

Latest · FY2025
6.61B DKK
Year-over-year change
+21.8%
4-year CAGR
+5.8%

Deferred Tax Liabilities vs competitors

How NVO compares with its peers on the latest reported figures

  • Peers report in different currencies, so deferred tax liabilities is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -56.4% is the lowest of 9, against a peer median of -10.1%.
  • Deferred tax liabilities amounts to 0.7% of total assets for NVO, versus a peer median of 1.4%.
NVO Competitors
Deferred Tax Liabilities for NVO and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
LLYEli Lilly and CompanyJun 2026$5.46B USD——3.8%
JNJJohnson & JohnsonSep 2026$4.84B USD-19.3%+19.4%2.4%
NVONovo Nordisk A/SJun 2026DKK 4.27B DKK-56.4%-2.2%0.7%
AZNAstraZeneca PLCSep 2026$3.61B USD+0.2%+6.0%3.0%
ABBVAbbVie Inc.Jun 2026$2.28B USD-10.8%-2.9%1.7%
PFEPfizer Inc.Jun 2026$1.96B USD-20.8%+32.9%1.0%
SNYSanofiJun 2026€1.55B EUR-9.4%-3.3%1.2%
MRKMerck & Co., Inc.Jun 2026$1.43B USD+0.4%-7.1%1.1%
AMGNAmgen Inc.Jun 2026$1.3B USD-6.1%+398.9%1.4%
GSKGSK plcJun 2026£301.17M GBP-42.8%+0.2%0.5%
Peer median (excluding NVO) —-10.1%+3.1%1.4%

Competitors are the stored peer set for NVO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

DKK
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents10.72B12.65B14.39B15.66B26.46B
Short-term Investments6.77B10.92B15.84B10.65B498M
Net Receivables46.8B57.51B75.26B87.41B75.7B
Inventory19.62B24.39B31.81B40.85B49.62B
Other Current Assets1.69B9.67B2.34B6.33B20.17B
Total Current Assets85.6B108.19B139.65B160.9B172.45B
Property, Plant & Equipment (Net)55.36B66.67B90.96B162.49B208.38B
Goodwill4.35B5.09B4.46B20.06B19.85B
Intangible Assets38.83B46.32B55.94B91.03B110.21B
Long-term Investments1.44B1.34B1.66B2.68B2.51B
Tax Assets8.67B13.43B20.38B24.63B23.65B
Other Non-current Assets267M206M1.43B4.02B5.86B
Total Non-current Assets108.91B133.06B174.84B304.9B370.45B
Total Assets194.51B241.26B314.49B465.8B542.9B
Account Payables8.87B15.59B25.61B28.85B19.76B
Short-term Debt12.86B480M5.3B11.78B12.02B
Tax Payables3.66B7.09B7.12B9.72B0
Deferred Revenue00000
Other Current Liabilities73.3B96.8B38.14B165.85B175.47B
Total Current Liabilities99.52B120.94B169.66B217.53B215.66B
Long-term Debt9.65B20.78B15.98B84.25B110.37B
Deferred Tax Liabilities5.27B7.06B10.16B5.43B6.61B
Deferred Revenue (Non-current)00000
Other Non-current Liabilities6.01B5.45B7.58B9.68B7.64B
Total Non-current Liabilities24.25B36.83B38.27B104.78B133.19B
Total Liabilities123.76B157.77B207.93B322.31B348.86B
Common Stock462M456M451M446M446M
Retained Earnings72B80.59B104.84B144.45B195.3B
Accumulated OCI(1.71B)2.45B1.28B(1.41B)(1.7B)
Other Stockholders Equity00000
Minority Interest00000
Total Equity70.75B83.49B106.56B143.49B194.05B
Total Debt26.65B25.78B27.01B102.79B130.96B
Net Debt15.93B13.13B12.61B87.13B104.49B

Novo Nordisk A/S

NYSE:NVO

Intrinsic Alpha fair value

Locked

Current Price

$39.43

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.